Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 15;63 Suppl 1(Suppl 1):S3-S11.
doi: 10.1093/cid/ciw219.

Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy

David L Wyles  1 , Mark S Sulkowski  2 , Douglas Dieterich  3
Affiliations
Review

Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy

David L Wyles et al. Clin Infect Dis. .

Abstract

The increased life expectancy of persons infected with human immunodeficiency virus (HIV) treated with antiretroviral therapy (ART) has resulted in renewed attention to non-HIV-related diseases exacerbated by HIV infection. Coinfection with hepatitis C virus (HCV) is a particular area of concern, as the global prevalence has been estimated at 2.5-5 million people. In this article, we discuss the epidemiology of HCV infection and reinfection, HCV-related liver disease progression in the era of effective ART, and the efficacy of emerging HCV treatment strategies in persons with HIV/HCV coinfection. New data regarding treatment of persons with HIV/HCV coinfection suggest that HCV treatment should be a priority in those with HIV. Results from recent studies using all-oral HCV regimens have shown high rates of sustained virologic response in both clinical trials and real-world settings. A multidisciplinary approach to HCV treatment in those with HIV is recommended for optimal patient management. Following HCV cure, practitioners also need to be mindful of the risks for HCV reinfection and educate patients on protective measures.

Keywords: HCV; HIV; HIV/HCV coinfection; direct acting-antivirals (DAAs); hepatitis C.

PubMed Disclaimer

References

    1. Weber R, Ruppik M, Rickenbach M et al. . Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195–207. - PubMed
    1. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord All-cause mortality in treated HIV-infected adults with CD4≥500/mm3 compared with the general population: evidence from a large European observational collaboration. Int J Epidemiol 2012; 41:433–45. - PubMed
    1. Nakagawa F, Lodwick RK, Smith CJ et al. . Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26:335–43. - PubMed
    1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831–7. - PubMed
    1. Frederick T, Burian P, Terrault N et al. . Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009; 23:915–23. - PMC - PubMed

Publication types

Substances